

Press Release

Alembic reports 11% growth in revenue for Q4 FY22 from INR 1280 Cr. in FY21 to INR 1416 Cr.

Financial Highlights

- India Branded Business up by 25% in Q4 from INR 358 Cr. in FY21 to INR 449 Cr.
- US Generics Business up by 17% in Q4 from INR 475 Cr. in FY21 to INR 557 Cr.
- India Branded Business up by 29% in FY22 from INR 1497 Cr. in FY21 to INR 1926 Cr.
- US portfolio strengthened with the acquisition of Aleor Dermaceuticals
- Company recommended dividend of Rs.10 per equity share i.e. 500%.

Vadodara, May 2nd, 2022

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 31st March 2022.

Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said "India Branded Business continues to deliver strong market beating growth in Q4. India Business witnessed market outperforming growth across most of the products and therapy areas."

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "The US Business grew 17% in the quarter. We continue to remain focused on the US Business hence we acquired the balance 40% stake in Aleor Dermaceuticals, making it a wholly owned subsidiary of the Company".

Net Profit After Tax for the quarter is Rs. 35 Cr. post charging off non-recurring expense of Rs. 188 Cr.



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in
CIN : L24230GJ2010PLC061123

Operational Highlights

International Generics

- 23 ANDA filed in FY22. Cumulative ANDA filings at 230.
- 23 ANDA approvals received in FY22 Cumulative ANDA approvals 160
- US Generics at Rs 557 Cr. in the quarter and at Rs 1666 Cr. for FY22.
- Ex-US International Formulations at Rs. 188 Crores in the quarter and at Rs 775 Cr. for FY22.

India Branded Business

- India Branded Business at Rs 449 Cr. in the quarter and at Rs 1926 Cr. (growth of 25% and 29% respectively) in the FY22.
- Acute & most specialty segments grew faster than IPM.

API

- API business at Rs 222 Cr. in the quarter and at Rs 939 Cr. for FY22.
- 3 DMFs were filed in the quarter.


Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q4 FY22	Q4 FY21	% Change	FY22	FY21	% Change
Formulation						
USA	557	475	17%	1666	2163	(23%)
Ex-US	188	233	(19%)	775	779	0%
India	449	358	25%	1926	1497	29%
API	222	214	4%	939	955	(2%)
Total	1416	1280	11%	5306	5393	(2%)

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837
 Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in
 CIN : L24230GJ2010PLC061123



About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5500+ are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 6637630 Email: mitanshu.shah@alembic.co.in
---	---



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in
CIN : L24230GJ2010PLC061123